Codexis to Present at Two Virtual Investment Conferences in September
09/08/2020 - 07:00 AM
REDWOOD CITY, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will present at two upcoming virtual investment conferences:
H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14, 2020 at 10:30 a.m. Eastern time (7:30 a.m. Pacific time).Cantor Fitzgerald Virtual Global Healthcare Conference in a fireside chat format on Thursday, September 17, 2020 at 8:00 a.m. Eastern time (5:00 a.m. Pacific time).A live webcast and replay of the presentations will be available on the Investors section of the company’s website, http://ir.codexis.com/ .
About Codexis, Inc.
Codexis is a leading protein engineering company that applies its proprietary CodeEvolver® technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics. Codexis’ proven technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes. For more information, see www.codexis.com .
Contact:
LHA Investor Relations
CDXS Rankings
#5181 Ranked by Stock Gains
CDXS Stock Data
Industry
Paint and Coating Manufacturing
Sector
Manufacturing
Tags
Process Industries, Chemicals: Specialty, Manufacturing, Paint and Coating Manufacturing
Country
US
City
Portland
About CDXS
codexis, inc. is a leading protein engineering company applying innovative technologies to unlock the power of proteins™. our proprietary codeevolver® technology platform enables the rapid development and production of highly optimized proteins, custom-designed for your application. codexis’ revolutionary approach to protein engineering starts with an understanding of the desired performance specifications and optimizes a protein specifically to fit these requirements. you get precisely the protein you need for the job you want it to do. guided by proprietary artificial intelligence software and advanced high-throughput screening systems, codexis is able to efficiently generate and introduce function-driven mutations to rapidly improve a protein for its target application. since 2002, codexis’ in-house biochemists, biologists and bioinformatics experts have worked closely with our clients to advance the technologies for protein optimization and production, enabling breakthrough develop
